Abstract
The development of malignant tumours and their immune regulation depends on a variety of factors including the presence or absence of tumour cell associated antigens (TAA) and the quantitative and qualitative representation of major histocompatibility complex (MHC) determinants in the tumour cells. Investigations of the latter and their importance in relation to host tumour interaction has been the main thrust of our research in this area over the last ten years. Increased or decreased expression of syngeneic Class I and Class II molecules as well as the expression of aberrant “allospecificities” may in different ways affect the immunosurveillance of tumours, their growth rate, as well as their metastatic potential. Our original experimental findings included the observations that certain tumour cells (a) selectively fail or express very weakly the specificities of one of the syngeneic H-2 Class I loci and/or (b) express novel H-2 “allospecificities” as determined by antibody testing.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bishop, C.E., Lewis, C.M. & Festenstein, H.: Dominant allele-specific regulation of expression of H-2Kk gene products revealed by somatic cell hybridisation. Somatic Cell Genetics, 8: 623–634, 1982.
Bonavida, B.: The SLJ/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumour interactions, and the regulation of tumour growth. Adv. Cancer Res., 38: 1–22, 1983.
Brickell, P., Latchman, D., Murphy D., Willison, K. & Rigby, P.W.J.: The Class I major histocompatibility antigen gene activated in a line of SV-40-transformed mouse cells is H-2Dd, not Qa/Tla. Nature 316: 162–163, 1985.
Festenstein, H., Garrido, F., Matossian-Rogers, A., Schirrmacher, V., Schmidt, W., DeGiorgi, L., Biasi, G. & Jaraquemada, D.: The major histocompatibility system, tumours and viruses, in: HLA System, New Aspects (ed. G.B. Ferrara ), Elsevier/North Holland Biomedical Press, p. 53–67, 1977.
Festenstein, H. & Schmidt, W.: Variation in MHC antigenic profiles of tumour cells and its biological effects. Immunological Rev., 60: 85–127, 1981.
Festenstein, H., Alonzo, A., Ferluga, J., Ma, B.L., Santamaria, O., Marelli, O., Schmidt, W. & Flavell, R.A.: Further molecular and functional evidence for the expression of H-2 allodeterminants on the AKR leukaemia, K36. Transpl. Proc., 15: 2107–2110, 1983.
Festenstein, H. & Hui, K.M.: Aberrant H-2-like allospecificities on K36.16 thymoma. Studies of radiobinding and immunoprecipitation with anti-H-2 monoclonal antibodies. J. Immunogenetics, 13: 113–116, 1986.
Garrido, F., Festenstein, H. & Schirrmacher, V.: Further evidence for derepression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature, 261: 705–707, 1976a.
Garrido, F., Schirrmacher, V. & Festenstein, H.: H-2-like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection. Nature, 259: 228–230, 1976b.
Garrido, F., Schirrmacher, V. & Festenstein, H.: Studies on H-2 specificities on mouse tumour cells by a new microradioassay. J. Immunogenetics, 4: 15–27.
Garrido, F., Schmidt, W. & Festenstein, H.: Immunogenetic studies on Meth.A vaccinia tumour cells in vivo and in vitro. J. Immunogenetics, 4: 115–125, 1977.
Hammerling, G.J., Klar, D., Katzav, S., Segal, S., Feldman, M., Wallich, R. & Hammerling, A.: Manipulation of metastasis and tumour growth by transfection with histocompatibility Class I genes. J. Immunogenetics, 13: 153–157, 1986.
Hui, K.M., Grosveld, F. & Festenstein, H.: Rejection of transplantable AKR leukaemia following MHC DNA-mediated cell transformation. Nature, 311: 750–752, 1984.
Hui, K.M., Matossian-Rogers, A., Festenstein, H. & Grosveld, F.: Demonstration of cytostasis and H-2Kk antigen expression in an H-2Kk-deficient AKR leukaemia following DNA-mediated gene transfer. Transpl. Proc., 17: 955–956, 1985.
Hui, K.M., Minamide, L., Prandoni, N., Festenstein, H. & Grosveld, F.G.: Structural variations in thè H-2 genes of AKR lymphomas. J. Immunogenetics, 13: 117–121, 1986.
Invernizzi, G. & Parmiani, G.: Tumour associated transplantation antigens of chemically induced sarcoma cross-reacting with allogeneic histocompatibility antigens. Nature, 254: 713, 1975.
Katzav, S., Tartokovsky, B., de Baetselier, P., Isakov, N., Feldman, M. & Segal, S.: H-2 and other major histocompatibility complexes; Biologic function. Transpl. Proc., 15: 162–170, 1983.
Labeta, M.O., Fernandez, N. & Festenstein, H.: Solubilisation effect of Nonidet P-40, Triton X-100 and CHAPS in the detection of MHC-like glycoproteins. (Submitted).
Lilly, F.: The inheritance of susceptibility to the Gross leukaemia virus in mice. Genetics, 53: 529, 1966.
Ljunggren, H-G. & Karre, K.: Variations in MHC antigen expression on tumours and its significance. Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression: opposing influences of T cell and natural killer mediated resistance. J. Immunogenetics, 13: 141–151, 1986.
Mann, D., Popovic, M., Sarin, P., Murray, C., Reitz, M.S., Strong, D.M., Haynes, B.F., Gallo, R.C. & Blattner, W.A.: Cell lines producing human T-cell lymphoma virus show altered HLA expression. Nature, 305: 58–59, 1983.
Marelli, O., Testorelli, C., Canti, G., Festenstein, H. & Nicolin, A.: Immunological cross-reactivity between H-2DK product and DTIC-treated H-2d lymphoma. J. Immunogenetics, 9: 407–412, 1982.
Martin, W.J.: Immune surveillance directed against derepressed cellular and viral antigens. Cell. Immunol., 15: 1, 1975.
Martin, W.J., Gibson, T.G., Martin, S.W. & Rice, J.M.: Derepressed alloantigen on lung tumour cells transplacentally induced, coded by H-2 liked gene. Science, 194: 532, 1976.
Meruello, D.: H-2D control of leukaemia susceptibility: mechanisms and implications. J. Immunogenetics, 7: 81–90, 1980.
Old, E., Boyse, E.A. & Stockert, E.: The G (Gross) leukaemia antigen. Cancer Res., 25: 813, 1965.
Old, L.J. & Stockert, E.: Immunogenetics of cell surface antigens of mouse leukaemia. Ann. Rev. Genet., 17: 127–160, 1977.
Parmiani, G.: Foreign histocompatibility determinants as tumour associated transplantation antigens of chemically induced murine fibrosarcoma. In: HLA System — New Aspects (ed. G.B. Ferrara ), Elsevier/North Holland Biomedical Press, p. 45, 1977.
Philipps, G., Stauss, H.J., Wortzel, R.D. & Schreiber, H.: Unusual or aberrant MHC antigen expression on tumours. A novel MHC Class I molecule as a tumour-specific antigen. Correlation between the antibody-defined and the CTL-defined target structure. J. of Immunogenetics, 13: 93–99, 1986.
Schäfer, A. & Schmidt, W.: Resistance to cellular immune response in AKR leukaemias. Eur. J. Immunol., 16: 753, 1986.
Schmidt, W., Leben, L., Atfield, G. & Festenstein, H.: Variation of expression of histocompatibility antigens on tumour cells: absence of H-2Kk gene products from a Gross virus induced leukaemia in BALB.K. Immunogenetics, 14: 323–339, 1981.
Schmidt, W., Alonzo, A., Leben, L. & Festenstein, H.: Differential regulation of H-2 antigen expression in tumours and its biological consequences. Transpl. Proc., 13: 1814–1818, 1981.
Schmidt, W. & Festenstein, H.: Resistance to cell-mediated cytotoxicity is correlated with reduction of H-2K gene products in AKR leukaemia. Immunogenetics, 16: 257–264, 1982.
Schmidt, W.: H-2 specific antibodies induced by injection of syngeneic leukaemia cells. Immunogenetics, 25: 215–221, 1987.
Schrier, P.I., Bernards, R., Vaessen, R.T.M.J., Houweling, A. & van der Eb, A.J.: Expression of Class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature, 309: 771, 1983.
Sonoda, S., Yashiki, S., Takahashi, K., Matsumoto, T., Matsumoto, M., Yunoki, K., Sato, K., Inoko, H. & Tsuji, K.: Altered expression of MHC Class I and II antigens in T and B lymphocytes of adult T cell leukaemia-lymphoma patients. Proceedings from the Third Asia-Oceania Histocompatibility Workshop Conference (ed. M. Aizawa), Hokkaido University Press, Sapporo, Japan, p.628–631.
Stauss, H.J., Linsk, R., Fischer, A., Watts, S., Banasiak, D., Haberman, A., Clark, I., Forman, J., McMillan, M., Schreiber, H. & Goodenow, R.S.: The MHC genes encoding the tumour specific Class I antigens expressed on a murine fibrosarcoma. J. Immunogenetics, 13: 101–112, 1986.
Steinmetz, M., Frelinger, J.S., Fisher, D., Hunkapiller, T., Pereira, D., Weissman, S.M., Uehara, H., Nathenson, S. & Hood, L.: Three cDNA clones encoding mouse transplantation antigens: Homology to Immunoglobulin genes. Cell, 24: 125–134, 1981.
Tanaka, K., Hayashi, H., Hamada, C., Khoury, G. & Gilbert, J.: Expression of major histocompatibility complex Class I antigens as a strategy for the potentiation of immune recognition of tumour cells. Proc. Natl. Acad. Sci. (USA), 83: 8723–8727, 1986.
Wallich, R., Bulbuc, N., Hammerling, G., Katzav, S., Segal, S. & Feldman, M.: Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature, 315: 301, 1985.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer Science+Business Media New York
About this chapter
Cite this chapter
Festenstein, H., Labeta, M. (1987). MHC Antigen Expression in Malignant Tumours and Their Effects on Host-Tumour Interaction. In: David, C.S. (eds) H-2 Antigens. NATO ASI Series, vol 144. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0764-9_58
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0764-9_58
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0766-3
Online ISBN: 978-1-4757-0764-9
eBook Packages: Springer Book Archive